English-speaking eye clinics in Tokyo offering eye exams, treatment, emergency care and long-term vision support for residents and visitors.

A new study published in the journal of Contact Lens & Anterior Eye showed that the risk of keratoconus and corneal erosion is considerably higher in individuals with allergic ...

Credit: Glaukos. Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

Glaukos’ Epioxa allows cross-linking therapy for keratoconus without requiring an incision. The biotech expects to launch the drug early next year. The FDA has signed off on Glaukos’ corneal therapy, ...

The topical therapy offers a less invasive approach to corneal cross-linking, with commercial availability anticipated in early 2026. Glaukos announced FDA approval for its novel topical therapy ...

Corneal crosslinking may be suitable for patients with keratoconus and stromal thicknesses thinner than 400 μm. Corneal crosslinking (CXL) improves visual and keratometric parameters in patients with ...